Overview

Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The phase I study is to determine the maximum tolerated dose and dose limiting toxicity of docetaxel and nedaplatin prescribed twice weekly in combination with concurrent chest radiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Docetaxel
Nedaplatin